American Shared Hospital Services (AMS) 10-Q 15 May 14 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	1-May-14
Document Information [Line Items]	'	'
Entity Registrant Name	'AMERICAN SHARED HOSPITAL SERVICES	'
Entity Central Index Key	'0000744825	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'AMS	'
Entity Common Stock, Shares Outstanding	'	4,608,370
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Period Focus	'Q1	'
Document Fiscal Year Focus	'2014	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$957,000	$1,909,000
Restricted cash	50,000	50,000
Accounts receivable, net of allowance for doubtful accounts of $100,000 in 2014 and $100,000 in 2013	4,889,000	4,522,000
Other receivables	236,000	143,000
Prepaid expenses and other current assets	729,000	740,000
Current deferred tax assets	394,000	342,000
Total current assets	7,255,000	7,706,000
Property and equipment:	'	'
Medical equipment and facilities	86,746,000	86,712,000
Office equipment	749,000	749,000
Deposits and construction in progress	7,857,000	7,719,000
Property and equipment	95,352,000	95,180,000
Accumulated depreciation and amortization	-45,430,000	-43,799,000
Net property and equipment	49,922,000	51,381,000
Certificate of deposit	9,000,000	9,000,000
Investment in equity securities	2,701,000	2,701,000
Other assets	905,000	954,000
Total assets	69,783,000	71,742,000
Current liabilities:	'	'
Accounts payable	895,000	572,000
Employee compensation and benefits	181,000	204,000
Customer deposits/deferred revenue	697,000	709,000
Other accrued liabilities	1,496,000	1,529,000
Current portion of long-term debt	4,581,000	4,804,000
Current portion of obligations under capital leases	3,980,000	3,967,000
Total current liabilities	11,830,000	11,785,000
Long-term debt, less current portion	10,007,000	10,740,000
Long-term capital leases, less current portion	11,858,000	12,950,000
Advances on line of credit	8,900,000	8,840,000
Deferred income taxes	3,372,000	3,372,000
Shareholders' equity:	'	'
Common stock (4,608,000 shares at March 31, 2014 and 4,609,000 shares at December 31, 2013)	8,576,000	8,578,000
Additional paid-in capital	5,016,000	4,990,000
Accumulated other comprehensive loss	-441,000	-442,000
Retained earnings	6,398,000	6,494,000
Total equity-American Shared Hospital Services	19,549,000	19,620,000
Non-controlling interest in subsidiary	4,267,000	4,435,000
Total shareholders' equity	23,816,000	24,055,000
Total liabilities and shareholders' equity	$69,783,000	$71,742,000

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Allowance for doubtful accounts (in dollars)	$100,000	$100,000
Common stock, shares issued	4,608,000	4,609,000
Common stock, shares outstanding	4,608,000	4,609,000

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Medical services revenue	$4,064,000	$4,668,000
Costs of revenue:	'	'
Maintenance and supplies	487,000	381,000
Depreciation and amortization	1,611,000	1,474,000
Other direct operating costs	677,000	695,000
Costs of revenue	2,775,000	2,550,000
Gross Margin	1,289,000	2,118,000
Selling and administrative expense	922,000	1,235,000
Interest expense	470,000	471,000
Operating (loss) income	-103,000	412,000
Gain (loss) foreign currency transactions	15,000	-141,000
Interest and other income	9,000	14,000
(Loss) income before income taxes	-79,000	285,000
Income tax (benefit) expense	-30,000	52,000
Net (loss) income	-49,000	233,000
Less: Net income attributable to non-controlling interest	-47,000	-208,000
Net (loss) income attributable to American Shared Hospital Services	($96,000)	$25,000
Net (loss) income per share:	'	'
(Loss) earnings per common share - basic (in dollars per share)	($0.02)	$0.01
(Loss) earnings per common share - diluted (in dollars per share)	($0.02)	$0.01

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Net (loss) income attributable to American Shared Hospital Services	($96,000)	$25,000
Other comprehensive income:	'	'
Foreign currency translation adjustments	1,000	22,000
Total comprehensive (loss) income	-95,000	47,000
Less comprehensive income attributable to the non-controlling interest	0	14,000
Comprehensive (loss) income attributable to American Shared Hospital Services	($95,000)	$33,000

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive (Loss) Income [Member]	Retained Earnings [Member]	Parent [Member]	Noncontrolling Interest [Member]
Balances at Dec. 31, 2011	$25,171,000	$8,606,000	$4,828,000	$0	$6,768,000	$20,202,000	$4,969,000
Balances (in shares) at Dec. 31, 2011	'	4,611,000	'	'	'	'	'
Repurchase of common stock	-28,000	-28,000	0	0	0	-28,000	0
Repurchase of common stock (in shares)	'	-9,000	'	'	'	'	'
Stock based compensation expense	74,000	0	74,000	0	0	74,000	0
Stock based compensation expense (in shares)	'	4,000	'	'	'	'	'
Investment in subsidiaries by non-controlling interests	217,000	0	0	0	0	0	217,000
Cumulative translation adjustment	-637,000	0	0	-357,000	0	-357,000	-280,000
Cash distributions to non-controlling interests	-780,000	0	0	0	0	0	-780,000
Net income (loss)	813,000	0	0	0	38,000	38,000	775,000
Balances at Dec. 31, 2012	24,830,000	8,578,000	4,902,000	-357,000	6,806,000	19,929,000	4,901,000
Balances (in shares) at Dec. 31, 2012	'	4,606,000	'	'	'	'	'
Stock based compensation expense	88,000	0	88,000	0	0	88,000	0
Stock based compensation expense (in shares)	'	3,000	'	'	'	'	'
Investment in subsidiaries by non-controlling interests	184,000	0	0	0	0	0	184,000
Cumulative translation adjustment	-142,000	0	0	-85,000	0	-85,000	-57,000
Cash distributions to non-controlling interests	-792,000	0	0	0	0	0	-792,000
Net income (loss)	-113,000	0	0	0	-312,000	-312,000	199,000
Balances at Dec. 31, 2013	24,055,000	8,578,000	4,990,000	-442,000	6,494,000	19,620,000	4,435,000
Balances (in shares) at Dec. 31, 2013	'	4,609,000	'	'	'	'	'
Repurchase of common stock	-2,000	-2,000	0	0	0	-2,000	0
Repurchase of common stock (in shares)	'	-1,000	'	'	'	'	'
Stock based compensation expense	26,000	0	26,000	0	0	26,000	0
Stock based compensation expense (in shares)	'	0	'	'	'	'	'
Investment in subsidiaries by non-controlling interests	59,000	0	0	0	0	0	59,000
Cumulative translation adjustment	1,000	0	0	1,000	0	1,000	0
Cash distributions to non-controlling interests	-274,000	0	0	0	0	0	-274,000
Net income (loss)	-49,000	0	0	0	-96,000	-96,000	47,000
Balances at Mar. 31, 2014	$23,816,000	$8,576,000	$5,016,000	($441,000)	$6,398,000	$19,549,000	$4,267,000
Balances (in shares) at Mar. 31, 2014	'	4,608,000	'	'	'	'	'

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Operating activities:	'	'
Net (loss) income	($49,000)	$233,000
Adjustments to reconcile net income to net cash from operating activities:	'	'
Depreciation and amortization	1,679,000	1,485,000
Deferred income tax	-52,000	-1,000
(Gain) loss on foreign currency transactions	-15,000	141,000
Stock based compensation expense	26,000	37,000
Changes in operating assets and liabilities:	'	'
Receivables	-456,000	-714,000
Prepaid expenses and other assets	0	137,000
Customer deposits/deferred revenue	-12,000	0
Accounts payable and accrued liabilities	283,000	562,000
Net cash from operating activities	1,404,000	1,880,000
Investing activities:	'	'
Payment for purchase of property and equipment	-147,000	-119,000
Net cash from investing activities	-147,000	-119,000
Financing activities:	'	'
Principal payments on long-term debt	-956,000	-790,000
Principal payments on capital leases	-1,079,000	-956,000
Advances on line of credit	60,000	0
Capital contributions from non-controlling interests	59,000	15,000
Distributions to non-controlling interests	-274,000	-291,000
Repurchase common stock	-2,000	-291,000
Net cash from financing activities	-2,192,000	-2,313,000
Effect of changes in foreign exchange rates on cash	-17,000	-1,000
Net change in cash and cash equivalents	-952,000	-553,000
Cash and cash equivalents at beginning of period	1,909,000	1,564,000
Cash and cash equivalents at end of period	957,000	1,011,000
Cash paid during the period for:	'	'
Interest	541,000	532,000
Income taxes	$21,000	$10,000

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	Note 1.	Basis of Presentation
	In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of only normal recurring accruals) necessary to present fairly American Shared Hospital Services’ consolidated financial position as of March 31, 2014 and the results of its operations for the three month period ended March 31, 2014 and 2013, which results are not necessarily indicative of results on an annualized basis. Consolidated balance sheet amounts as of December 31, 2013 have been derived from audited financial statements.
	These unaudited consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2013 included in the Company’s 10-K filed with the Securities and Exchange Commission.
	These financial statements include the accounts of American Shared Hospital Services (the “Company”) and its wholly-owned subsidiaries: OR21, Inc. (“OR21”); MedLeader.com, Inc. (“MedLeader”); and American Shared Radiosurgery Services (“ASRS”); ASRS’ majority-owned subsidiary, GK Financing, LLC (“GKF”); GKF’s wholly-owned subsidiaries, GK Financing U.K., Limited (“GKUK”), Instituto de Gamma Knife del Pacifico S.A.C. (“GKPeru”), GKFDB#1, LLC (“GKFDB1”), and GKFDB#2, LLC (“GKFDB2”). GKFDB1 and GKFDB2 each own 50% of the subsidiary GKF do Brasil Equipamentos Medicos LTDA (“GKF do Brasil”); ASHS’ majority owned subsidiary, Long Beach Equipment, LLC (“LBE”), GKF’s majority owned subsidiaries, Albuquerque GK Equipment, LLC (“AGKE”), Jacksonville GK Equipment, LLC (“JGKE”) and EWRS, LLC (“EWRS”), and EWRS’ wholly owned subsidiary, EWRS Tibbi Cihazlar Ticaret Ltd Sti (“EWRS Turkey ”).
	The Company through its majority-owned subsidiary, GKF, provided Gamma Knife units to nineteen medical centers as of March 31, 2014 in the states of Arkansas, California, Connecticut, Florida, Illinois, Massachusetts, Mississippi, Nevada, New Jersey, New Mexico, New York, Tennessee, Oklahoma, Ohio, Texas and Wisconsin, and in Turkey.
	GKF also provides radiation therapy equipment to the radiation therapy department at the Gamma Knife site in Turkey. The Company also directly provides radiation therapy and related equipment, including Intensity Modulated Radiation Therapy (“IMRT”), Image Guided Radiation Therapy (“IGRT”) and a CT Simulator to the radiation therapy department at an existing Gamma Knife site in the United States.
	The Company formed the subsidiaries GKUK, GKPeru, EWRS, EWRS Turkey and GKF do Brasil for the purposes of expanding its business internationally into the United Kingdom, Peru, Turkey and Brazil; LBE to provide proton beam therapy services in Long Beach, California; and AGKE and JGKE to provide Gamma Knife services in Albuquerque, New Mexico and Jacksonville, Florida. AGKE and EWRS Turkey began operation in the second quarter 2011 and JGKE began operation in the fourth quarter 2011. GKPeru is expected to begin operation in the latter part of 2014. GKUK is inactive and LBE is not expected to generate revenue in the next two years. The Company is in the final stages of liquidating GKF do Brazil and ASHS do Brazil.
	During 2013 and 2014, the Company’s partner in its Turkey operation, and its partners in the Jacksonville Gamma Knife operations have made investments in EWRS, and JGKE, respectively. These investments are included in the line item “Non-controlling interests in subsidiaries” in the Company’s financial statements.
	Based on guidance provided in accordance with ASC 830, Foreign Currency Matters (“ASC 830”), the Company analyzes its operations outside the United States to determine the functional currency of each operation. Management has determined that these operations are initially accounted for in U.S. Dollars since the primary transactions incurred are in U.S. Dollars and the Company provides significant funding towards the startup of the operation. When Management determines that an operation has become self-sufficient, the Company may change its accounting for the operation to the local currency from the U.S. Dollar, depending on the facts and circumstances. The Company determined that effective in the third quarter 2012, the functional currency for its Turkish operation, EWRS Turkey, was the Turkish Lira. Therefore, in accordance with ASC 830, EWRS Turkey’s balance sheet accounts were translated at rates in accordance with guidance provided under ASC 830, and accumulated losses and translation differences were recorded in accumulated other comprehensive loss, which is a separate component of equity.
	As of March 31, 2014 and December 31, 2013, EWRS Turkey’s balance sheet accounts were translated at rates in effect as of those dates, respectively, and income and expense accounts were translated at the weighted average rates of exchange during those respective periods. Translation adjustments resulting from this process were also recognized under accumulated other comprehensive loss. Gains and losses from foreign currency transactions are listed in the Company’s Consolidated Statements of Operations. The Company recorded a net foreign currency gain of $15,000 for the three month period ended March 31, 2014 and net foreign currency loss of approximately $141,000 for the three month period ended March 31, 2013.
	Based on guidance provided in accordance with 280 Segment Reporting (“ASC 280”), the Company has analyzed the factors that define an operating segment and determined that there is only one operating segment. The nineteen locations are aggregated into one reportable segment because, in the Company’s judgment, these operating segments have similar historical economic characteristics and are expected to have similar economic characteristics in the future. Furthermore, each operating segment utilizes the same business model and technologies, servicing the same end users (radiation therapy patients). All significant intercompany accounts and transactions have been eliminated in consolidation.

Per_Share_Amounts

Per Share Amounts	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	Note 2.	Per Share Amounts
	Per share information has been computed based on the weighted average number of common shares and dilutive common share equivalents outstanding. For the three months ended March 31, 2014 basic loss per share was computed using 4,608,000 common shares. For the three months ended March 31, 2013 basic earnings per share was computed using 4,606,000 common shares and diluted earnings per share was computed using 4,610,000 common shares and equivalents.
	Pursuant to United States Generally Accepted Accounting Principles (GAAP), potentially dilutive common stock equivalents, such as dilutive stock options are not considered when their inclusion in reporting earnings per share would be dilutive to reported losses incurred per share. Because the Company is reporting a loss for the quarter ending March 31, 2014, the potentially dilutive effects of approximately 525,000 of the Company’s stock options are not considered for this reporting period. The computation for 2013 excluded approximately 592,000 of the Company’s stock options because the strike price of the options was higher than the average market price during the quarter.

Stockbased_Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 3.	Stock-based Compensation
	On June 2, 2010, the Company’s shareholders approved an amendment and restatement of the 2006 Stock Incentive Plan (the “2006 Plan”). Among other things, the amendment and restatement renamed the 2006 Plan to the Incentive Compensation Plan (the “Plan”) and increased the number of shares of the Company’s common stock reserved for issuance under the Plan by an additional 880,000 shares from 750,000 shares to 1,630,000 shares. The shares are reserved for issuance to officers of the Company, other key employees, non-employee directors, and advisors. The Plan serves as successor to the Company’s previous two stock-based employee compensation plans, the 1995 and 2001 Stock Option Plans. The shares reserved under those two plans, including the shares of common stock subject to currently outstanding options under the plans, were transferred to the Plan, and no further grants or share issuances will be made under the 1995 and 2001 Plans. Under the Plan, there have been 146,000 restricted stock units granted, consisting primarily of annual automatic grants and deferred compensation to non-employee directors, and there are 551,000 options granted, of which 526,000 options are vested as of March 31, 2014.
	Compensation expense associated with the Company’s stock-based awards to employees is calculated using the Black-Scholes valuation model. The Company’s stock-based awards have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value estimates. The estimated fair value of the Company’s option grants is estimated using assumptions for expected life, volatility, dividend yield, and risk-free interest rate which are specific to each award. The estimated fair value of the Company’s options is amortized over the period during which an employee is required to provide service in exchange for the award, usually the vesting period. Accordingly, stock-based compensation cost before income tax effect in the amount of $26,000 is reflected in net income for the three month period ended March 31, 2014, compared to $37,000 in the same period in the prior year. There were no options issued and no options exercised during either of the three month periods ended March 31, 2014 or March 31, 2013. There were no excess income tax benefits to report.

Investment_in_Equity_Securitie

Investment in Equity Securities	3 Months Ended
	Mar. 31, 2014
Investments, All Other Investments [Abstract]	'
Cost-method Investments, Description [Text Block]	'
		Note 4.	Investment in Equity Securities
	As of March 31, 2014 and December 31, 2013 the Company had a $2,701,000 investment in the common stock of Mevion Medical Systems, Inc. (“Mevion”), formerly Still River Systems, Inc., representing an approximate 0.77% interest in Mevion. The Company accounts for this investment under the cost method.
	The Company carries its investment in Mevion at cost and reviews it for impairment on a quarterly basis, or as events or circumstances might indicate that the carrying value of the investment may not be recoverable. The Company evaluated this investment for impairment at December 31, 2013 and reviewed it at March 31, 2014 in light of both current market conditions and the ongoing needs of Mevion to raise cash to continue its development of the first compact, single room proton beam radiation therapy (“PBRT”) system. Based on its analysis, the Company estimates that there is currently an unrealized loss (impairment) of approximately $2.4 million.
	In assessing whether the impairment is other than temporary, we evaluated the length of time and extent to which market value has been below cost, the financial condition and near term prospects of Mevion and our ability and intent to retain our investment for a period sufficient to allow for an anticipated recovery in the market value. Although the investment is not without risk, and the manufacture of the first unit has taken longer than originally anticipated, the Company believes that the current market value is a temporary situation and the successful clinical operation of the first MEVION S250 system at Barnes Jewish Hospital and Mevion’s significant revenue backlog provide a significantly higher potential valuation.
	Mevion’s first PBRT unit at Barnes Jewish Hospital is complete. The first treatment at Barnes Jewish Hospital was performed in mid-December 2013. Mevion is continuing the installation process at five other sites, including the Company’s site at University of Florida Cancer Center at Orlando Health (formerly the MD Anderson Cancer Center Orlando). The Company’s first site broke ground for construction in September 2012 and the accelerator is expected to be delivered in Fall 2014.

Line_of_Credit

Line of Credit	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	Note 5.	Line of Credit
	The Company has a $9,000,000 renewable line of credit with the Bank of America (the “Bank”) that has been in place since June 2004 and has a maturity date of August 1, 2015. The line of credit is drawn on from time to time as needed for equipment purchases and working capital. Amounts drawn against the line of credit are at an interest rate per year equal to the Bank’s prime rate minus 0.5 percentage point, or alternately, at the Company’s discretion, the LIBOR rate plus 1.0 percentage point, and are secured by the Company’s cash invested with the Bank. The Company is in compliance with all debt covenants required. The weighted average interest rate during the first three months of 2014 was 1.50%. At March 31, 2014, $8,900,000 was borrowed against the line of credit, compared to $8,840,000 at December 31, 2013.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	Note 6.	Fair Value of Financial Instruments
	The Company’s disclosures of the fair value of financial instruments is based on a fair value hierarchy which prioritizes the inputs to the valuation techniques used to measure fair value into three levels. Level 1 inputs are unadjusted quoted market prices in active markets for identical assets and liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for assets or liabilities, and reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the asset or liability.
	The estimated fair value of the Company’s assets and liabilities as of March 31, 2014 and December 31, 2013 were as follows (in thousands):
			Level 1		Level 2		Level 3		Total		Carrying
											Value
	31-Mar-14
	Assets:
	Cash, cash equivalents, restricted cash		$	1,007					$	1,007	$	1,007
	Receivables			4,889						4,889		4,889
	Certificate of deposit			9,000						9,000		9,000
	Investment in equity securities							300		300		2,701
	Total		$	14,896	$	-	$	300	$	15,196	$	17,597
	Liabilities
	Accounts payable and other accrued liabilities		$	3,269					$	3,269	$	3,360
	Advances on line of credit			8,900						8,900		8,900
	Debt obligations							30,203		30,203		30,426
	Total		$	12,169	$	-	$	30,203	$	42,372	$	42,686
	31-Dec-13
	Assets:
	Cash, cash equivalents, restricted cash		$	1,959					$	1,959	$	1,959
	Receivables			4,522						4,522		4,522
	Certificate of deposit			9,000						9,000		9,000
	Investment in equity securities							300		300		2,701
	Total		$	15,481	$	-	$	300	$	15,781	$	18,182
	Liabilities
	Accounts payable and other accrued liabilities		$	3,014					$	3,014	$	3,014
	Advances on line of credit			8,840						8,840		8,840
	Debt obligations							32,418		32,418		32,461
	Total		$	11,854	$	-	$	32,418	$	44,272	$	44,315

Repurchase_of_Common_Stock

Repurchase of Common Stock	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders Equity Note Disclosure [Text Block]	'
	Note 7.	Repurchase of Common Stock
	In 1999 and 2001, the Board of Directors approved resolutions authorizing the Company to repurchase up to a total of 1,000,000 shares of its own stock on the open market, which the Board reaffirmed in 2008. There were 1,000 shares repurchased in the first quarter of 2014. There were no shares repurchased in 2013. There are approximately 72,000 shares remaining under this repurchase authorization.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	Note 8.	Income Taxes
	We generally calculate our effective income tax rate at the end of an interim period using an estimate of the annual effective income tax rate expected to be applicable for the full fiscal year. However, when a reliable estimate of the annual effective income tax rate cannot be made, we compute our provision for income taxes using the actual effective income tax rate for the year-to-date period. Our effective income tax rate is highly influenced by the amount of the nondeductible stock-based compensation associated with grants of our common stock options and the results from foreign operations. A small change in estimated annual pretax income (loss) can produce a significant variance in the annual effective income tax rate given the expected amount of these items. Because of this variability, a reliable estimate of the annual effective income tax rate for 2014 cannot be made. As a result, we have computed our provision (benefit) for income taxes for the three months ended March 31, 2014 by applying the actual effective tax rate to income (loss) for the period.

Reclassification

Reclassification	3 Months Ended
	Mar. 31, 2014
Disclosure of Reclassification [Abstract]	'
Disclosure of Reclassification [Text Block]	'
	Note 9.	Reclassification
	Certain comparative amounts in the consolidated financial statements have been reclassified to conform to the current quarter’s presentation.

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
	The estimated fair value of the Company’s assets and liabilities as of March 31, 2014 and December 31, 2013 were as follows (in thousands):
		Level 1		Level 2		Level 3		Total		Carrying
										Value
	31-Mar-14
	Assets:
	Cash, cash equivalents, restricted cash	$	1,007					$	1,007	$	1,007
	Receivables		4,889						4,889		4,889
	Certificate of deposit		9,000						9,000		9,000
	Investment in equity securities						300		300		2,701
	Total	$	14,896	$	-	$	300	$	15,196	$	17,597
	Liabilities
	Accounts payable and other accrued liabilities	$	3,269					$	3,269	$	3,360
	Advances on line of credit		8,900						8,900		8,900
	Debt obligations						30,203		30,203		30,426
	Total	$	12,169	$	-	$	30,203	$	42,372	$	42,686
	31-Dec-13
	Assets:
	Cash, cash equivalents, restricted cash	$	1,959					$	1,959	$	1,959
	Receivables		4,522						4,522		4,522
	Certificate of deposit		9,000						9,000		9,000
	Investment in equity securities						300		300		2,701
	Total	$	15,481	$	-	$	300	$	15,781	$	18,182
	Liabilities
	Accounts payable and other accrued liabilities	$	3,014					$	3,014	$	3,014
	Advances on line of credit		8,840						8,840		8,840
	Debt obligations						32,418		32,418		32,461
	Total	$	11,854	$	-	$	32,418	$	44,272	$	44,315

Basis_of_Presentation_Details_

Basis of Presentation (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Foreign Currency Transaction Gain, before Tax	$15,000	'
Foreign Currency Transaction Loss, before Tax	'	$141,000
GKFDB#1, LLC [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Noncontrolling Interest, Ownership Percentage by Parent	50.00%	'
GKFDB#2, LLC [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Noncontrolling Interest, Ownership Percentage by Parent	50.00%	'

Per_Share_Amounts_Details_Text

Per Share Amounts (Details Textual)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Weighted Average Number of Shares Outstanding, Basic	4,608,000	4,606,000
Weighted Average Number of Shares Outstanding, Diluted	'	4,610,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	525,000	592,000

Stockbased_Compensation_Detail

Stock-based Compensation (Details Textual) (USD $)	3 Months Ended			1 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Jun. 30, 2010	Jun. 30, 2010	Jun. 30, 2010
			Restricted Stock Units (RSUs) [Member]	Incentive Compensation Plan [Member]	Incentive Compensation Plan [Member]	Incentive Compensation Plan [Member]
					Maximum [Member]	Minimum [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'	'	'
Common Stock, Capital Shares Reserved for Future Issuance	'	'	'	'	1,630,000	750,000
Increase (Decrease) in Common Stock Capital Shares Reserved for Future Issuance	'	'	'	880,000	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	551,000	'	146,000	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	526,000	'	'	'	'	'
Employee Benefits and Share-based Compensation	$26,000	$37,000	'	'	'	'

Investment_in_Equity_Securitie1

Investment in Equity Securities (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Schedule of Cost-method Investments [Line Items]	'	'
Cost Method Investments	$2,701,000	$2,701,000
Investment Percentage in Common Stock	0.77%	'
Unrealized Gain (Loss) on Investments	$2,400,000	'

Line_of_Credit_Details_Textual

Line of Credit (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Line of Credit Facility [Line Items]	'	'
Line of Credit Facility, Maximum Amount Outstanding	$9,000,000	'
Line of Credit Facility, Expiration Date	1-Aug-15	'
Debt Instrument, Interest Rate Terms	'the Banks prime rate minus 0.5 percentage point, or alternately, at the Companys discretion, the LIBOR rate plus 1.0 percentage point	'
Debt, Weighted Average Interest Rate	1.50%	'
Long-term Line of Credit, Noncurrent	$8,900,000	$8,840,000

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Assets, Carrying Value:	'	'
Cash, cash equivalents, restricted cash, Carrying Value	$1,007,000	$1,959,000
Receivables, Carrying Value	4,889,000	4,522,000
Certificate of deposit, Carrying Value	9,000,000	9,000,000
Investment in equity securities, Carrying Value	2,701,000	2,701,000
Total, Carrying Value	17,597,000	18,182,000
Liabilities, Carrying Value	'	'
Accounts payable and other accrued liabilities, Carrying Value	3,360,000	3,014,000
Advances on line of credit, Carrying Value	8,900,000	8,840,000
Debt obligations, Carrying Value	30,426,000	32,461,000
Total, Carrying Value	42,686,000	44,315,000
Assets, Fair Value:	'	'
Cash, cash equivalents, restricted cash, Fair Value	1,007,000	1,959,000
Receivables, Fair Value	4,889,000	4,522,000
Certificate of deposit, Fair Value	9,000,000	9,000,000
Investment in equity securities, Fair Value	300,000	300,000
Total, Fair Value	15,196,000	15,781,000
Liabilities, Fair Value	'	'
Accounts payable and other accrued liabilities, Fair Value	3,269,000	3,014,000
Advances on line of credit, Fair Value	8,900,000	8,840,000
Debt obligations, Fair Value	30,203,000	32,418,000
Total, Fair Value	42,372,000	44,272,000
Fair Value, Inputs, Level 1 [Member]	'	'
Assets, Fair Value:	'	'
Cash, cash equivalents, restricted cash, Fair Value	1,007,000	1,959,000
Receivables, Fair Value	4,889,000	4,522,000
Certificate of deposit, Fair Value	9,000,000	9,000,000
Investment in equity securities, Fair Value	'	'
Total, Fair Value	14,896,000	15,481,000
Liabilities, Fair Value	'	'
Accounts payable and other accrued liabilities, Fair Value	3,269,000	3,014,000
Advances on line of credit, Fair Value	8,900,000	8,840,000
Debt obligations, Fair Value	'	'
Total, Fair Value	12,169,000	11,854,000
Fair Value, Inputs, Level 2 [Member]	'	'
Assets, Fair Value:	'	'
Cash, cash equivalents, restricted cash, Fair Value	'	'
Receivables, Fair Value	'	'
Certificate of deposit, Fair Value	'	'
Investment in equity securities, Fair Value	'	'
Total, Fair Value	0	0
Liabilities, Fair Value	'	'
Accounts payable and other accrued liabilities, Fair Value	'	'
Advances on line of credit, Fair Value	'	'
Debt obligations, Fair Value	'	'
Total, Fair Value	0	0
Fair Value, Inputs, Level 3 [Member]	'	'
Assets, Fair Value:	'	'
Cash, cash equivalents, restricted cash, Fair Value	'	'
Receivables, Fair Value	'	'
Certificate of deposit, Fair Value	'	'
Investment in equity securities, Fair Value	300,000	300,000
Total, Fair Value	300,000	300,000
Liabilities, Fair Value	'	'
Accounts payable and other accrued liabilities, Fair Value	'	'
Advances on line of credit, Fair Value	'	'
Debt obligations, Fair Value	30,203,000	32,418,000
Total, Fair Value	$30,203,000	$32,418,000

Repurchase_of_Common_Stock_Det

Repurchase of Common Stock (Details Textual)	Mar. 31, 2014	Dec. 31, 2008	Mar. 31, 2014
			Share Repurchase Program [Member]
Equity, Class of Treasury Stock [Line Items]	'	'	'
Stock Repurchase Program, Number of Shares Authorized to be Repurchased	'	1,000,000	'
Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased	72,000	'	'
Stock Repurchased During Period, Shares	'	'	1,000